Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 45.65 | 16.21 | 14.02 | 80.81 | 167.39 | 11.80 | 9.56 | 108.78 | 0.87 | 3.13 | 20.27 | 3.70 | 8.21 | 2.73 | 4.61 | 29.50 | 12.04 | 2.05 | 2.83 | 12.74 | 9.16 |
| — | +37.4% | +46.5% | -25.7% | +19117.5% | +277.4% | -52.8% | +2838.6% | -89.4% | +14.5% | +339.3% | -87.5% | -31.8% | +33.2% | +63.0% | +131.6% | +31.5% | -74.7% | -87.2% | +157.7% | -20.7% | |
| P/S Ratio | 7.66 | 4.66 | 3.67 | 4.76 | 4.91 | 4.66 | 3.46 | 29.74 | 0.52 | 0.71 | 5.23 | 8.14 | 1.12 | 1.23 | 1.50 | 2.19 | 1.36 | 1.30 | 1.69 | 2.82 | 2.50 |
| — | +0.1% | +6.0% | -84.0% | +844.8% | +552.4% | -33.8% | +265.3% | -53.6% | -42.1% | +248.7% | +271.3% | -17.9% | -4.9% | -11.5% | -22.1% | -45.4% | -58.5% | -50.3% | -17.8% | -24.0% | |
| P/B Ratio | 5.76 | 3.50 | 2.85 | 3.02 | 3.55 | 3.31 | 2.42 | 2.53 | 0.36 | 0.50 | 0.53 | 0.60 | 0.66 | 0.75 | 0.87 | 0.91 | 1.03 | 0.79 | 0.88 | 1.05 | 1.18 |
| — | +5.6% | +17.8% | +19.1% | +873.3% | +568.0% | +358.9% | +318.9% | -44.9% | -33.6% | -39.5% | -33.9% | -35.4% | -6.0% | -0.6% | -13.0% | -12.9% | -41.4% | -34.1% | -2.6% | -16.1% | |
| P/FCF | 39.09 | 10.87 | 88.29 | — | 18.02 | 8.91 | 61.59 | 12.18 | 11.18 | 1.99 | 18.96 | 22.84 | 3.26 | 3.00 | 18.46 | 1.98 | 24.31 | 2.81 | 6.01 | 11.26 | 37.81 |
| — | +22.0% | +43.4% | — | +61.2% | +347.4% | +224.8% | -46.7% | +242.6% | -33.5% | +2.7% | +1050.5% | -86.6% | +6.7% | +206.8% | -82.4% | -35.7% | -85.6% | -75.3% | +140.5% | — | |
| EV / EBITDA | 30.88 | 13.61 | 11.96 | 28.07 | 61.88 | 9.13 | 7.75 | 95.66 | 0.52 | 1.18 | 12.99 | 11.59 | 0.99 | 1.38 | 2.46 | 7.11 | 1.78 | 1.43 | 2.34 | 6.60 | 5.06 |
| — | +49.1% | +54.3% | -70.7% | +11695.4% | +671.3% | -40.3% | +725.6% | -47.0% | -14.1% | +428.9% | +62.9% | -44.4% | -3.9% | +5.0% | +7.7% | -64.9% | -73.6% | -55.8% | +10.0% | -4.0% | |
| EV / EBIT | 29.29 | 13.70 | 12.79 | 28.07 | 61.88 | 8.98 | 6.75 | 78.09 | 0.50 | 1.23 | 10.48 | 5.91 | 1.84 | 0.91 | 2.55 | 8.03 | 1.79 | 1.48 | 2.46 | 6.17 | 4.55 |
| — | +52.6% | +89.5% | -64.1% | +12205.7% | +627.3% | -35.6% | +1221.9% | -72.6% | +35.6% | +311.4% | -26.5% | +2.7% | -38.5% | +3.7% | +30.1% | -60.7% | -66.2% | -56.8% | +149.0% | -49.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.7% | 92.6% | 92.7% | 92.7% | 92.3% | 94.3% | 93.8% | 94.1% | 94.8% | 95.1% | 96.4% | 95.5% | 97.3% | 98.3% | 99.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -1.8% | -1.2% | -1.5% | -2.6% | -0.8% | -2.7% | -1.5% | -2.6% | -3.3% | -3.1% | -4.5% | -2.7% | -1.7% | -0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | 33.6% | 37.2% | 35.2% | 25.1% | 23.0% | 44.9% | 38.9% | 26.3% | 33.5% | 37.9% | 30.3% | 19.2% | 35.7% | 35.8% | 35.2% | 14.7% | 50.1% | 47.2% | 39.4% | 24.3% | 30.9% |
| — | -17.3% | -9.5% | -4.5% | -31.5% | +18.4% | +28.5% | +36.7% | -6.1% | +6.1% | -14.0% | +30.7% | -28.8% | -24.3% | -10.7% | -39.3% | +62.3% | +22.6% | -1.2% | -27.9% | -28.8% | |
| Net Margin | 25.9% | 28.8% | 26.2% | 5.9% | 2.9% | 39.2% | 36.3% | 27.3% | 59.7% | 22.9% | 26.1% | 31.8% | 13.7% | 44.7% | 32.0% | 7.4% | 10.0% | 63.2% | 59.8% | 21.9% | 27.3% |
| — | -26.6% | -27.8% | -78.3% | -95.1% | +71.7% | +39.4% | -14.3% | +336.3% | -48.8% | -18.6% | +329.7% | +36.7% | -29.3% | -46.5% | -66.2% | -63.4% | +64.0% | +285.4% | -68.3% | -3.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 5.6% | 5.2% | 0.9% | 0.5% | 7.3% | 6.6% | 0.1% | 11.2% | 4.0% | 0.6% | 0.6% | 2.0% | 7.0% | 4.8% | 0.8% | 1.9% | 10.1% | 8.0% | 2.1% | 3.3% |
| — | -23.3% | -20.6% | +570.5% | -95.2% | +80.2% | +925.1% | -77.0% | +449.1% | -42.7% | -86.6% | -22.3% | +7.1% | -30.4% | -40.4% | -62.8% | -42.1% | +135.6% | +428.3% | -63.0% | +6.6% | |
| ROA | 3.3% | 2.7% | 2.4% | 0.4% | 0.3% | 5.9% | 5.4% | 0.1% | 9.0% | 3.2% | 0.5% | 0.5% | 1.8% | 6.3% | 4.3% | 0.7% | 1.7% | 8.9% | 7.2% | 1.9% | 2.9% |
| — | -54.8% | -54.7% | +281.1% | -96.5% | +83.9% | +897.5% | -79.3% | +395.7% | -48.3% | -87.4% | -23.1% | +7.3% | -29.5% | -40.7% | -63.0% | -42.6% | +131.8% | +427.2% | -62.9% | +8.2% | |
| ROIC | 5.0% | 3.4% | 3.2% | 1.8% | 2.7% | 8.3% | 6.7% | 0.1% | 6.0% | 5.8% | 0.8% | 0.5% | 7.1% | 7.0% | 6.4% | 1.9% | 11.1% | 9.0% | 6.4% | 2.8% | 4.6% |
| — | -59.0% | -52.8% | +1258.7% | -55.4% | +42.9% | +783.3% | -72.7% | -16.5% | -16.5% | -88.1% | -74.2% | -35.6% | -22.6% | +0.4% | -33.3% | +143.1% | +63.1% | +28.4% | -13.7% | -24.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.93 | 0.82 | 0.89 | 0.94 | 0.93 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
| — | +3224.2% | +3071.1% | +3273.7% | +3217.1% | -20.1% | -15.2% | -10.2% | +15.1% | +21.3% | +17.8% | +1.9% | +11.3% | +8.0% | +7.8% | +66.5% | +14.3% | +14.9% | +18.4% | -2.7% | +14.8% | |
| Debt / EBITDA | 4.10 | 11.11 | 12.18 | 28.66 | 54.97 | 0.30 | 0.39 | 4.61 | 0.47 | 0.45 | 4.08 | 7.83 | 0.45 | 0.45 | 0.53 | 1.76 | 0.23 | 0.32 | 0.48 | 0.72 | 0.49 |
| — | +3631.0% | +2993.8% | +521.2% | +11509.1% | -33.3% | -90.3% | -41.1% | +6.4% | -0.3% | +672.6% | +344.8% | +96.0% | +42.0% | +8.9% | +143.7% | -53.5% | -31.6% | -7.7% | +12.6% | +44.5% | |
| Current Ratio | 2.02 | 2.45 | 2.46 | 2.18 | 2.02 | 6.03 | 6.22 | 6.22 | 5.25 | 5.17 | 5.03 | 12.46 | 13.34 | 11.38 | 14.93 | 14.44 | 15.48 | 9.62 | 13.11 | 17.31 | 14.50 |
| — | -59.3% | -60.5% | -64.9% | -61.5% | +16.7% | +23.7% | -50.1% | -60.7% | -54.6% | -66.3% | -13.7% | -13.8% | +18.3% | +13.8% | -16.6% | +6.8% | -19.8% | -12.8% | +12.2% | -3.3% | |
| Quick Ratio | 2.01 | 2.43 | 2.44 | 2.17 | 2.01 | 6.01 | 6.20 | 6.20 | 5.24 | 5.15 | 5.02 | 12.42 | 13.32 | 11.36 | 14.90 | 14.44 | 15.48 | 9.62 | 13.11 | 17.31 | 14.50 |
| — | -59.6% | -60.6% | -65.0% | -61.6% | +16.7% | +23.5% | -50.1% | -60.7% | -54.6% | -66.3% | -14.0% | -14.0% | +18.1% | +13.6% | -16.6% | +6.8% | -19.8% | -12.8% | +12.2% | -3.3% | |
| Interest Coverage | 20.74 | 4.19 | 3.68 | 1.66 | 2.25 | 161.67 | 48.00 | 49.80 | 41.98 | 117.72 | 16.32 | 63.25 | 155.33 | 334.88 | 209.71 | 69.50 | 522.60 | 321.83 | 207.83 | 154.00 | 323.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GMAB stock.
Genmab A/S's current P/E is 45.7x. The average P/E over the last 4 quarters is 69.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Genmab A/S's current operating margin is 33.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Genmab A/S's business trajectory between earnings reports.